Related Experiment Video
Updated: Jul 30, 2025
Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
Published on: November 23, 2014
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Zhen-Ling Liu1, Huan-Huan Chen1, Li-Li Zheng1
1Department of Medicinal Chemistry, Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, 210009, Nanjing, China.
Abstract:
Angiogenesis, the formation of new blood vessels, is a complex and dynamic process regulated by various pro- and anti-angiogenic molecules, which plays a crucial role in tumor growth, invasion, and metastasis. With the advances in molecular and cellular biology, various biomolecules such as growth factors, chemokines, and adhesion factors involved in tumor angiogenesis has gradually been elucidated. Targeted therapeutic research based on these molecules has driven anti-angiogenic treatment to become a promising strategy in anti-tumor therapy. The most widely used anti-angiogenic agents include monoclonal antibodies and tyrosine kinase inhibitors (TKIs) targeting vascular endothelial growth factor (VEGF) pathway. However, the clinical benefit of this modality has still been limited due to several defects such as adverse events, acquired drug resistance, tumor recurrence, and lack of validated biomarkers, which impel further research on mechanisms of tumor angiogenesis, the development of multiple drugs and the combination therapy to figure out how to improve the therapeutic efficacy. Here, we broadly summarize various signaling pathways in tumor angiogenesis and discuss the development and current challenges of anti-angiogenic therapy. We also propose several new promising approaches to improve anti-angiogenic efficacy and provide a perspective for the development and research of anti-angiogenic therapy.
Insights
Anti-angiogenic therapies targeting tumor blood vessel formation show promise but face limitations like drug resistance and side effects. Further research into signaling pathways and combination therapies is crucial for improving anti-cancer treatment efficacy.
Area of Science:
- Oncology
- Molecular Biology
- Biomedical Engineering
Background:
- Angiogenesis, the formation of new blood vessels, is vital for tumor growth, invasion, and metastasis.
- Biomolecules regulating tumor angiogenesis, including growth factors and chemokines, are increasingly understood.
- Anti-angiogenic therapy, particularly targeting the vascular endothelial growth factor (VEGF) pathway, is a key strategy in cancer treatment.
Purpose of the Study:
- To summarize signaling pathways involved in tumor angiogenesis.
- To discuss the development and current challenges of anti-angiogenic therapy.
- To propose novel approaches for enhancing anti-angiogenic efficacy.
Main Methods:
- Review of current literature on tumor angiogenesis signaling pathways.
- Analysis of the development and limitations of existing anti-angiogenic therapies.
- Exploration of emerging strategies for improving therapeutic outcomes.
Main Results:
- Tumor angiogenesis is a complex process regulated by multiple molecular factors.
- Current anti-angiogenic therapies, such as VEGF inhibitors, have limitations including adverse events and drug resistance.
- Further research is needed to overcome these challenges and improve treatment efficacy.
Conclusions:
- Understanding tumor angiogenesis pathways is critical for developing effective cancer therapies.
- Combination therapies and novel approaches are necessary to enhance the clinical benefit of anti-angiogenic treatments.
- Continued research and biomarker development are essential for advancing anti-angiogenic therapy.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:24Regulation of Angiogenesis and Blood Supply
01:10Mechanism of Angiogenesis
01:41Non-Canonical Wnt Signaling Pathways
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...